Home/Filings/4/0001209191-23-042453
4//SEC Filing

Nabulsi Azmi 4

Accession 0001209191-23-042453

CIK 0001783183other

Filed

Jul 16, 8:00 PM ET

Accepted

Jul 17, 5:00 PM ET

Size

10.9 KB

Accession

0001209191-23-042453

Insider Transaction Report

Form 4
Period: 2023-07-14
Nabulsi Azmi
Chief Operating Officer
Transactions
  • Award

    Common Stock

    2023-07-14+110,000209,567 total
  • Disposition to Issuer

    Stock Option

    2023-07-14150,0000 total
    Exercise: $39.11Exp: 2031-01-27Common Stock (150,000 underlying)
  • Disposition to Issuer

    Stock Option

    2023-07-1470,0000 total
    Exercise: $32.20Exp: 2030-06-30Common Stock (70,000 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    785,700
  • Common Stock

    (indirect: By 401(k))
    3,578.93
Footnotes (2)
  • [F1]On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]Includes 1,233.71 shares acquired under the Phathom Pharmaceuticals, Inc. 401(k) plan.

Issuer

Phathom Pharmaceuticals, Inc.

CIK 0001783183

Entity typeother

Related Parties

1
  • filerCIK 0001791412

Filing Metadata

Form type
4
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 5:00 PM ET
Size
10.9 KB